Atossa Genetics Inc - Asset Resilience Ratio
Atossa Genetics Inc (ATOS) has an Asset Resilience Ratio of 0.39% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2017)
This chart shows how Atossa Genetics Inc's Asset Resilience Ratio has changed over time. Check how strategically is Atossa Genetics Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Atossa Genetics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Atossa Genetics Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $55.00K | 0.39% |
| Total Liquid Assets | $55.00K | 0.39% |
Asset Resilience Insights
- Limited Liquidity: Atossa Genetics Inc maintains only 0.39% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Atossa Genetics Inc Industry Peers by Asset Resilience Ratio
Compare Atossa Genetics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Atossa Genetics Inc (2011–2017)
The table below shows the annual Asset Resilience Ratio data for Atossa Genetics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.67% | $55.00K | $8.16 Million | -0.65pp |
| 2016-12-31 | 1.33% | $55.00K | $4.14 Million | -3.08pp |
| 2015-12-31 | 4.40% | $275.00K | $6.24 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $11.76 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $12.01 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $6.83 Million | -- |
| 2011-12-31 | 32.55% | $1.00 Million | $3.07 Million | -- |
About Atossa Genetics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more